Amgen stock rose early Wednesday, though the biotech behemoth said the FDA placed one of its obesity treatments on clinical ...

Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

Shares of Amgen (AMGN) fell in after-hours trading after the biotechnology company reported earnings for its fourth quarter ...

Product sales rose 11%, led by 14% volume growth. Products including Repatha, Blincyto and Tezspire all posted at least double digit sales growth, the company said. For the current year, Amgen expects ...

The Tax Cuts and Jobs Act of 2017 reconfigured the tax code. Did it also enable a pharmaceutical giant to invest in Wake County? Or did it simply increase their profits?

These products underscore Amgen's capacity to seize growth opportunities, particularly in rare disease markets. Additionally, the operating margin expanded to 26.5%, reflecting operational ...

Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...

All of a sudden, Amgen stock is up 15% since late December to around $299. Its rise helped push up the healthcare sector up just over 7% since hitting a bottom in late December. The better-than ...

Amgen Inc (AMGN) reports a 19% revenue increase, driven by strong product sales and strategic international expansions, ...

Amgen, Inc. ( NASDAQ: AMGN) Oppenheimer 35th Annual Healthcare Life Sciences Conference Call February 12, 2025 11:20 AM ET Narimon Honarpour - Senior Vice President, Global Development Justin Claeys - ...

Amgen posted 11% revenue growth in the fourth quarter, with at least double-digit growth from ten products. The biotechnology company on Tuesday reported a profit of $627 million, or $1.16 a share ...